JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

October 13, 2020

In this guide, we will discuss several challenges in developing antibody-based therapeutics,
including assessing pharmacokinetic characteristics, selecting efficacious variants, and
determining the appropriate dose. We'll also provide details on how the JAX Therapeutic Evaluation Services can give fast and cost-effective analyses of IgG-based therapies.

JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

A New Way to Study Cytokine Release Syndrome

Poster: A Humanized In Vivo System to Predict Antibody-induced Cytokine Release Syndrome

A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

CRS: FAQs

Choosing the Appropriate Humanized FcRn Mouse Model to Test the Pharmacokinetics of Antibody Therapeutics

The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

Poster: Choosing the Appropriate Immune System- Humanized Mouse Model for Immuno-Modulatory Therapies

Human Immune System Engrafted Mice and Their Role in Human Antibody-Based Drug Development

Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors

Testing the Efficacy of Immuno-Modulatory Antibodies in Humanized Mice

The ABC’s of CAR T Cell Therapies